President Donald Trump and billionaire investor Mark Cuban found rare common ground on prescription drug pricing reform in May 2026, as both publicly supported measures to lower medication costs for American consumers.
Trump reiterated campaign pledges to reduce drug prices through importation and negotiation, while Cuban’s Cost Plus Drugs venture has marketed transparent pricing models directly to patients. Policy observers said the alignment reflects bipartisan voter pressure over pharmacy bills.
Congressional Democrats have pushed for Medicare negotiation expansion, while Republicans emphasize supply chain competition. Cuban has testified before lawmakers on disrupting pharmacy benefit manager middlemen.
Industry groups cautioned that price caps without addressing research and development costs could limit access to innovative treatments. Federal agencies continue reviewing Trump-era proposals to link U.S. prices to lower international benchmarks.
Cost Plus Drugs sells select generics at transparent prices plus fixed margins, bypassing traditional pharmacy benefit structures. Trump administration officials have discussed most-favored-nation pricing models in Medicare negotiations. The pharmaceutical industry spent heavily lobbying against importation provisions in prior congressional packages. Polls show drug costs remain a top voter concern across party lines heading into midterm elections.
House committees scheduled hearings on pharmacy benefit manager reform alongside pricing proposals. Trump previously signed executive orders on drug importation that faced implementation delays. Cuban appeared at Capitol Hill events with bipartisan lawmakers discussing transparent cash pricing models.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://dailycuratednews.substack.com/p/news-headlines-may-22-2026